
OmniAb

High-Specificity OmniAb Antibodies for Bispecific Applications

13th World Bispecific Summit, Boston Christel Iffland, Ph.D. VP of Antibody Technologies

September 21, 2022






Antibody Repertoires and Bispecific Antibodies

ACTIVE PROGRAMS

CLINICAL PROGRAMS



Combining sources provides partners even more diverse repertoires and new target access

Common light chain techs being used for flexibility and bispecific program optionality



Approved and Clinical Partner Bispecific Pipeline

ONE APPROVED PRODUCT AND 10 ACTIVE CLINICAL OMNIAB-DERIVED ANTIBODIES

Partner	Program	Source Animal	Area	Targets
	TECVAYLI®	OmniRat	Oncology	BCMA x CD3
Genmab	GEN1046	OmniRat	Oncology	PD-L1 x 4-1BB
	APVO436	OmniMouse	Oncology	CD123 x CD3
	JNJ-67371244	OmniMouse	Oncology	CD33 x CD3
	JNJ-70218902	OmniRat	Oncology	Undisclosed
	JNJ-78306358	OmniRat	Oncology	HLA-G x CD3
Genmab	GEN1047	OmniRat	Oncology	B7H4 x CD3
abbvie †	TNB-383B	OmniFlic	Oncology	BCMA x CD3
AstraZeneca	TNB-486	OmniFlic	Oncology	CD19 x CD3
AMGEN [†]	AMG 340	OmniFlic	Oncology	PSMA x CD3
Boehringer Ingelheim	Undisclosed	OmniChicken	Undisclosed	Undisclosed

+ Programs discovered by Teneobio

TECVAYLI® granted conditional marketing authorization (CMA) by the EMA Janssen Marks First Approval Worldwide for TECVAYLI® (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma | Johnson & Johnson (jnj.com)




Rodent Platforms

• Endogenous Ig genes inactivated

- Expression of full human V gene diversity
- Streamlined conversion into fully human molecule

Well-validated transgene design utilizes rodent constant regions for robust immune responses from the B-cell repertoire








OmniChicken Platform

POWERED BY EVOLUTION





Greater evolutionary distance yields greater immunogenicity and more antibody diversity




Engineering of lg Loci

ADAPTATION TO CHICKEN GENE CONVERSION PROCESS




DmniAb

Gene conversion



Human V's selected for:

- High expression level, stability, ubiquity
- High sequence diversity in CDRs
- Low sequence diversity in FWs




Common Light Chain Platforms

STANDARD IGG FORMAT TO DE-RISK DOWNSTREAM DEVELOPMENT¹ OF BISPECIFIC MABS



Rearranged human VK3-15 light chain combined with diversifying heavy chain




Simple reformatting from monospecific into bispecific for efficient production





"Germlining" human VK3-15 light chain combined with diversifying heavy chain




Monospecific IgG

Common light chain for OmniFlic and OmniClic allows interchangeability between the platforms



Omni*dAb*[™]: Heavy Chain Only Transgenic Chickens

HCO STRATEGY USING TRUNCATED LIGHT CHAIN (TLC)




- Normal chicken heavy chain can express as VH alone
- VHH transgene in development




Ultralong CDRH3s Create Novel Binding Domains

UNIQUE STRUCTURAL FEATURES OF ULTRALONG H3 ANTIBODIES



- Novel structure may enable targeting epitopes unreachable by standard antibodies
- Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies[™]




Stanfield, et.al. Sci Adv (2020) 6(20): eaba0468.



OmniTaur



Picobodies™ as Building Blocks for Novel Therapeutics



OmniAb


OmniAb Antibody Repertoires

OPTIONS AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES


Host	V genes	Structural and immunological features	Benefits for therapeutics discovery and development
S OmniMouse	Full human V gene diversity Choice of light chain isotype	Diverse V gene usage and mixed genetic backgrounds	Widely accessible and flexible workflows
S OmniRat	Full human V gene diversity Choice of light chain isotype	Diverse V gene usage and mixed genetic backgrounds Distinctive target recognition	Industry standard Widely accessible and flexible workflows Extensive track record
OmniChicken	Single framework VH3/VK3 or VH3/VL1	Evolutionarily divergent host system for robust immune responses	Diverse and new epitope coverage High homology targets Excellent physical properties
S omni F lic	Full human VH gene diversity with non-diversifying VK3	Fixed light chain for bispecific applications	Bispecific applications leveraging standard IgG format
OmniĈlic	Single framework VH3/non-diversifying VK3	Fixed light chain for bispecific applications	Diverse epitope coverage Excellent physical properties Ease of manufacturing
Omni <i>dAb</i>	Single camelized human VH framework with truncated LC	Domain antibody of the "VHH" type	Diverse and new epitope coverage from human single-domain format, 12-15kD Building blocks for multispecific molecules
OmniTaur	Single framework VH4/VL1	Ultralong CDR-H3's for enormous structural diversity	Access cryptic epitopes Unique modalities (picobodies™) Building blocks for multispecific molecules



Screening Technology: xPloration®



Leveraging Biological Intelligence with Computational Tools





The OmniAb Platform

	Create Diverse	Screen Antibody	Identify the
	Antibody Pools	Candidates	Right Antibody
	Create Diverse Pools of High-Quality	Screen Millions of Cells to Find	Further Characterize, Select &
	Naturally Optimized Antibodies	Potential Therapeutic Candidates	Optimize the Right Antibody
Technologies	Computational Antigen Design & Proprietary Reagents OmniRat OmniChicken	xPloration High-Throughput Single Cell Screening	 Custom Bioinformatics Next Generation Sequencing (NGS) Hit Expansion
OmniAb T	Robust Antibodies for Any Target Comnicia Bispecific Antibody Generation Robust Antibodies for Any Target Comnicial Comnicial Cow-inspired Antibodies for Difficult Targets	Gel Encapsulated Microenvironment (GEM) Single Cell Screening	 Comprehensive Functional Characterization Proprietary Ion Channel Assays

Technology offering addresses the most critical challenges of antibody discovery



OmniAb

THANK YOU TO THE OMNIAB TEAM!

www.OmniAb.com

